

# **CENTER FOR DRUG EVALUATION AND RESEARCH**

***APPLICATION NUMBER:***  
**21-559**

**MICROBIOLOGY REVIEW**

# **Product Quality Microbiology Review**

## **Review for HFD-510**

**29 January 2003**

**NDA: 21-559**

### **Drug Product Name**

**Proprietary:** Infuvite® Adult — (pharmacy bulk package)

**Non-proprietary:** vitamins for infusion

**Drug Product Classification:** Multidose Injectable

**Review Number: 1**

### **Subject of this Review**

**Submission Date:** 14 August 2002

**Receipt Date:** 16 August 2002

**Consult Date:** 21 August 2002

**Date Assigned for Review:** 27 September 2002

### **Applicant/Sponsor**

**Name:** Sabex Pharmaceutical Products

**Address:** 145 Jules-Leger, Boucherville, QC, Canada

**Representative:** Leonor Ferreira

**Telephone:** (450)641-4903 ext. 2161

**Name of Reviewer:** Paul Stinavage

**Conclusion:** The application is recommended for approval on the basis of sterility assurance.

## Product Quality Microbiology Data Sheet

- A.
1. **TYPE OF SUPPLEMENT:** Prior Approval
  2. **SUPPLEMENT PROVIDES FOR:** Addition of a pharmacy bulk package.
  3. **MANUFACTURING SITES:** Boucherville (Quebec), Canada
  4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Intravenous
  5. **METHOD(S) OF STERILIZATION:** \_\_\_\_\_
  6. **PHARMACOLOGICAL CATEGORY:** The product is indicated as a daily multivitamin supplement for adults and children aged 11 and older receiving parenteral nutrition.
- B. **SUPPORTING/RELATED DOCUMENTS:** NDA 21-163, NDA 21-265, DMF
- C. **REMARKS:** The product will be manufactured by:

Sabex  
145 Jules-Leger Street  
Boucherville, QC, Canada  
J4B7K8

The supplement references NDA 21-163 for Infuvite Adult which was approved 13 June 2001. The applicant states that the subject product contains the same active ingredients as Infuvite Adult and is manufactured using identical processes.

This review was originally issued to NDA 21-163/SLR-006 dated 07 October 2002 because the reviewer was unaware that the NDA number had changed as a result it involving a pharmacy bulk package. That submission (NDA 21-163/SLR-006) has been deleted from the DFS system. The review (NDA 21-559 dated 29 January 2003) is unchanged from the original and is being reissued to the correct DFS file.

filename: n21559.doc

---

**Executive Summary****I. Recommendations**

- A. Recommendation on Approvability – The application is recommended for approval on the basis of sterility assurance.
- B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable -

**II. Summary of Microbiology Assessments**

- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology –
- B. Brief Description of Microbiology Deficiencies – none

**III. Administrative**

- A. Reviewer's Signature \_\_\_\_\_
- B. Endorsement Block  
P. Stinavage  
P.H. Cooney
- C. CC Block  
cc:  
Original NDA 21-163  
HFD-510/Division File/NDA 21-163/S. McCort

1 Page(s) Withheld

,

**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**

/s/  
-----

•Paul Stinavage  
1/29/03 06:25:16 AM  
MICROBIOLOGIST  
Reissue of review for NDA 21-163/SLR-006 as a result  
of change in NDA number to NDA 21-559.

— Peter Cooney  
1/29/03-08:20:15 AM  
MICROBIOLOGIST